GLP-1RA reduces risk of CV events associated with overweight and obesity Medical Education on ReachMD

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Overview
AHA 2023 Michael Lincoff shares the results of the SELECT trial. “This trial is the first to show a weight-management therapy in a rigorous randomized trial to reduce the risk of CV events associated with overweight and obesity, and now positions overweight and obesity as a modifiable risk factor for CVD” said Lincoff.
Educational information
This video was recorded during the AHA Scientific Sessions 2023 in Philadelphia, PA, USA.
Faculty
Michael Lincoff, MD is an interventional cardiologist and Vice Chairman for Research of the Department of Cardiovascular Medicine at the Cleveland Clinic in Cleveland, OH, USA. He is also the Director of the Cleveland Clinic Coordinating Center for Clinical Research.
Disclosures
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read a summary of the SELECT trial
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Recommended

Details

Presenters

Overview
AHA 2023 Michael Lincoff shares the results of the SELECT trial. “This trial is the first to show a weight-management therapy in a rigorous randomized trial to reduce the risk of CV events associated with overweight and obesity, and now positions overweight and obesity as a modifiable risk factor for CVD” said Lincoff.
Educational information
This video was recorded during the AHA Scientific Sessions 2023 in Philadelphia, PA, USA.
Faculty
Michael Lincoff, MD is an interventional cardiologist and Vice Chairman for Research of the Department of Cardiovascular Medicine at the Cleveland Clinic in Cleveland, OH, USA. He is also the Director of the Cleveland Clinic Coordinating Center for Clinical Research.
Disclosures
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read a summary of the SELECT trial
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

GLP-1RA reduces risk of CV events associated with overweight and obesity